← Leaderboards
Aaron Elliott Lisberg
University Of California Los Angeles
$1,551,185
Attributed
$1,816,874
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $531.4K · FY2020–25$1M$750K$500K$250K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,816,874 · 2
By mechanism
K08$1,285,495 · 1
R01$531,379 · 1
Top collaborators
- David B Shackelford1 shared
Most similar at University Of California Los Angeles
Same institution · by research overlap
- Antoni Ribas$28,929,216
- Robert M Prins$8,963,397
- Linda M Liau$8,990,878
- James S. Economou$9,911,213
- Edward B Garon$6,470,653
Others in their field
Other Emerging Leaders on “Tumor”
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Lynn Briscoe · Leidos Biomedical Research, Inc.$120,794,323
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$105,180,681
- Leonard Freedmand · Leidos Biomedical Research, Inc.$78,762,245
- Connie Suders · Leidos Biomedical Research, Inc.$67,882,919
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
Research focus
TumorCancer PatientMediatingTherapy DevelopmentPublishingImmune Checkpoint InhibitorExhibitsMalignant Neoplasm Of LungPatient-Focused OutcomesSamplingUnited StatesResponseNon-Small-Cell Lung CarcinomaMortalityCancer EtiologyClinical Trials DesignAntigensAutologous Dendritic CellsClinical DataAutologousAntigen-Presenting CellsAdenovirus VectorChemokineClinical Research
Grant awards (6)
Investigating mitochondrial networks as a critical determinant of response to antibody drug conjugates in advanced NSCLC$531,379
R01 · FY2025 · CA · contact PI
Intratumoral Administration of CCL21-gene Modified Dendritic Cell With Intravenous Pembrolizumab for Advanced NSCLC$257,099
K08 · FY2024 · CA · contact PI
Intratumoral Administration of CCL21-gene Modified Dendritic Cell With Intravenous Pembrolizumab for Advanced NSCLC$257,099
K08 · FY2023 · CA · contact PI
Intratumoral Administration of CCL21-gene Modified Dendritic Cell With Intravenous Pembrolizumab for Advanced NSCLC$257,099
K08 · FY2022 · CA · contact PI
Intratumoral Administration of CCL21-gene Modified Dendritic Cell With Intravenous Pembrolizumab for Advanced NSCLC$257,099
K08 · FY2021 · CA · contact PI
Intratumoral Administration of CCL21-gene Modified Dendritic Cell With Intravenous Pembrolizumab for Advanced NSCLC$257,099
K08 · FY2020 · CA · contact PI